These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 9219787)

  • 21. Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up.
    Bresci G; Parisi G; Gambardella L; Banti S; Bertoni M; Rindi G; Capria A
    Int J Clin Pharmacol Res; 1997; 17(1):17-22. PubMed ID: 9403349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
    Mantzaris GJ; Archavlis E; Christoforidis P; Kourtessas D; Amberiadis P; Florakis N; Petraki K; Spiliadi C; Triantafyllou G
    Am J Gastroenterol; 1997 Mar; 92(3):454-6. PubMed ID: 9068468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
    Fernández-Bañares F; Hinojosa J; Sánchez-Lombraña JL; Navarro E; Martínez-Salmerón JF; García-Pugés A; González-Huix F; Riera J; González-Lara V; Domínguez-Abascal F; Giné JJ; Moles J; Gomollón F; Gassull MA
    Am J Gastroenterol; 1999 Feb; 94(2):427-33. PubMed ID: 10022641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
    Yen EF; Kane SV; Ladabaum U
    Am J Gastroenterol; 2008 Dec; 103(12):3094-105. PubMed ID: 18775007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
    Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-ASA enema therapy.
    Hanauer SB
    Neth J Med; 1989 Jun; 35 Suppl 1():S11-20. PubMed ID: 2702307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study.
    Paoluzi OA; Iacopini F; Pica R; Crispino P; Marcheggiano A; Consolazio A; Rivera M; Paoluzi P
    Aliment Pharmacol Ther; 2005 May; 21(9):1111-9. PubMed ID: 15854173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
    Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
    Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.
    Singer MV; Schmausser H; Schönfeld G
    Hepatogastroenterology; 2006; 53(69):317-21. PubMed ID: 16795963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.